In March of 2004, Plexus Vaccine Inc was acquired by SIGA Technologies Inc. Plexus Vaccine Inc seeks to meet the threat of emerging pathogens of global importance by rapidly discovering and developing marketable synthetic vaccines, using advanced computational and experimental methods. The company's product pipeline targets therapeutic vaccine markets for chronic infection that it will develop internally and in alliance with strategic partners. Platform technology is supported by public funding for vaccines against plague and anthrax
